NEXMED

GLP-1 Microdosing (Ozempic, Mounjaro): What's Real and What's Marketing

GLP-1 microdosing is a trend with no studies behind it. What's real, what the risks are, and what safe alternative exists.

Nexmed Editorial · Updated 30 September 2026
GLP-1 Microdosing (Ozempic, Mounjaro): What's Real and What's Marketing

GLP-1 "microdosing" has become a social media trend: very small doses of semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), promoted for "metabolism," "inflammation," or weight loss with fewer side effects. It sounds convincing, but there are no studies supporting microdosing as it's being sold.

In short: microdosing has no definition, no protocol, and no long-term data. The large clinical trials tested standard doses. It's true that lower doses (but still approved ones) have a real effect, and that is something entirely different from internet microdosing, which is often done with unregulated products.

What "microdosing" means

The term is used for different things:

  • doses far below the lowest approved dose;
  • doses given less often than once a week;
  • "compounded" products (prepared by pharmacies, not by the manufacturer), sold online in vials;
  • splitting an injection pen or reusing single-use vials.

As a Harvard endocrinologist told STAT (May 2026), there isn't even a single definition of microdosing for weight loss.

What the studies say

There are no controlled clinical trials showing that microdosing produces lasting weight loss or that it is safer. The large obesity trials used standard doses: 1.7–2.4 mg of semaglutide and 5–15 mg of tirzepatide.

There are two real things that sometimes get mixed up with microdosing:

  1. Lower, but approved, doses work. For example, 5 mg of tirzepatide led to −15.0% in the SURMOUNT-1 trial. But 5 mg is an official maintenance dose, tested in thousands of patients, not a "microdose." See what the trials show for each dose.
  2. Lowering the dose in the maintenance phase has been studied. The SURMOUNT-MAINTAIN trial (2026) showed that switching to 5 mg after weight loss maintains a significant part of the result. Again, this involves an approved dose and a rigorous trial. Details in our article on SURMOUNT-MAINTAIN.

None of this validates "made-up" doses or products sold online under the microdosing label.

The real risks

1. You don't know what the product contains. Compounded products or those sold as "research peptides" don't go through the controls applied to approved medications. Concentration, purity, and sterility can't be verified.

2. Dosing errors. The smaller the dose and the more it's measured by hand, the easier it is to make a mistake. In 2024, the FDA reported cases in which patients gave themselves 5 to 20 times the intended dose, due to confusion between milliliters, milligrams, and "units" on the syringe. Details in our article on overdose.

3. Contamination. Reusing or splitting single-use vials increases the risk of infection.

4. A false sense of safety. "Low dose" doesn't mean "no risk." Pancreatitis, gallbladder problems, or dehydration can occur at low doses too, and without medical follow-up, warning signs can be missed.

5. A modest, uncertain result. At very low doses, weight loss, if it happens, tends to be modest, and without data it's unknown whether it lasts.

The difference between microdosing and the minimum effective dose

Microdosing (online)Minimum effective dose (with your doctor)
DoseArbitrary, often below approved dosesOne of the approved doses
ProductOften compounded or unregulatedApproved medication, with a calibrated pen
EvidenceNo studiesLarge clinical trials
Follow-upUsually noneDoctor, lab tests, weigh-ins

Whatever dose you and your prescriber agree on, a GLP-1 and peptide tracker such as Reko (partner app, iPhone) logs it in its own units and includes a reconstitution calculator; it does not suggest doses.

Conclusion

GLP-1 microdosing is, for now, a marketing concept with no data behind it. The valid idea behind it — that not everyone needs the maximum dose — does exist, but it applies to approved doses chosen with your doctor. And if you'd like a more convenient treatment, keep an eye on the next generation of GLP-1 drugs, including pills, which are in trials or already approved. If you want a treatment with fewer side effects or a lower cost, talk to your doctor about the minimum effective dose — don't buy "microdoses" online.

Frequently asked questions

Does microdosing Ozempic work? There are no clinical trials showing that microdosing produces lasting weight loss. The large trials used standard doses.

Is microdosing safer? That hasn't been shown. The products used are often unregulated, and hand-measured doses have led to overdoses reported by the FDA.

Where do microdosing products come from? Usually from compounded preparations or products sold online, which lack the quality control of approved medications.

How is it different from a lower dose prescribed by a doctor? A lower dose prescribed by a doctor is one of the approved doses, given with the original injection pen and medically monitored. Microdosing has none of that.

Can I take low doses to avoid side effects? Talk to your doctor. The prescribing information allows delaying a dose increase or returning to the previous dose if significant gastrointestinal effects occur.

Read next

Useful calculators

Instead of made-up doses, see the official dosing schedule for each medication:

The "GLP-1 Dose" series

  1. The minimum effective GLP-1 dose: do you need the maximum dose?
  2. Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
  3. Lowering the dose after weight loss: the SURMOUNT-MAINTAIN trial
  4. GLP-1 microdosing: what's real and what's marketing
  5. Ozempic overdose: why you shouldn't calculate your own dose
  6. Reducing your GLP-1 dose: how to talk to your doctor

Sources

  • STAT News. GLP-1 microdosing is popular, but there's little evidence it works (May 29, 2026).
  • U.S. Food and Drug Administration. Alert on dosing errors associated with compounded semaglutide (July 26, 2024).
  • Jastreboff AM et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
  • SURMOUNT-MAINTAIN. Lancet. 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2

Educational material, updated September 2026. It does not replace a medical consultation. Do not change the dose, frequency, or method of administration of a medication without the agreement of the doctor who prescribed it.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1